Current fixed-duration CLL regimens are not MRD-guided, so the test result does not alter the treatment plan. While a negative result is prognostically favorable, its main clinical utility is to provide reassurance. A detectable result can cause unnecessary patient anxiety.

Though they sound similar, "double hit" and "double expressor" lymphomas are different entities. "Double hit" refers to genetic rearrangements (MYC and BCL2/BCL6), carrying the worst prognosis. "Double expressor" refers to protein overexpression without genetic rearrangement, conferring an intermediate prognosis that is better than double hit.

Surprisingly, patients with high-risk cytogenetics, a typically poor prognostic factor in multiple myeloma, were equally represented in both the long-term remission group and the group that progressed after Siltacel treatment. This suggests CAR-T therapy may overcome traditional risk stratification.

Although continuous BTK inhibitors have the most prospective data for high-risk CLL (17p/TP53 mutations), some highly motivated patients still opt for fixed-duration treatment. This requires a detailed conversation where clinicians must explain the trade-off: achieving a treatment-free period may come at the cost of needing second-line therapy sooner.

The combination of a Notch1 mutation and a specific IGHV stereotype (439 subset 8) creates an extremely high risk for early Richter's transformation in CLL. This finding warrants consideration of immediate combination therapy, even if the patient doesn't meet standard treatment criteria.

When considering escalating therapy for a patient with a high-risk p53 mutation, clinicians are adopting a key checkpoint: confirming the absence of a concurrent POLE mutation. The presence of a POLE mutation is thought to mitigate the aggressiveness of p53-mutated tumors, potentially making treatment escalation unnecessary.

In current CLL practice, a positive MRD result after fixed-duration therapy does not trigger a change in treatment, such as extending therapy. It serves as a prognostic tool to inform the patient and physician about the likely duration of remission and the need for closer monitoring.

A key clinical nuance in CLL is that not all prognostic markers are static. The IGHV mutation status remains unchanged, requiring a one-time test. However, chromosomal abnormalities like deletion 17p can evolve, necessitating re-evaluation at each relapse to guide subsequent therapy choices and adapt the treatment strategy.

A negative Minimal Residual Disease (MRD) result is not a universal surrogate for Progression-Free Survival (PFS). Its predictive power is context-dependent; it's meaningful when comparing similar treatments (e.g., BTKi + BCL2i vs. another BTKi + BCL2i), but less so when comparing entirely different drug classes.